Innoviva, Inc. (INVA) |
|
13.17 0.01 (0.08%)
|
09-27 16:00 |
|
Open: |
13.16 |
Pre. Close: |
13.16 |
|
High:
|
13.365 |
Low:
|
13.04 |
|
Volume:
|
354,447 |
Market Cap:
|
857(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:20:09 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 15.68 One year: 18.32 |
| Support: |
Support1: 12.76 Support2: 12.35 |
| Resistance: |
Resistance1: 13.43 Resistance2: 15.68 |
| Pivot: |
12.72 |
| Moving Average: |
MA(5): 13.04 MA(20): 12.72
MA(100): 12.97 MA(250): 12.68 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 81.4 %D(3): 80 |
| RSI: |
RSI(14): 58.7 |
| 52-week: |
High: 13.89 Low: 10.64 |
| Average Vol(K): |
3-Month: 530 (K) 10-Days: 878 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INVA ] has closed below upper band by 6.2%. Bollinger Bands are 8.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.38 - 13.43 |
13.43 - 13.48 |
|
Low:
|
12.9 - 12.97 |
12.97 - 13.03 |
|
Close:
|
13.07 - 13.16 |
13.16 - 13.26 |
|
Company Description |
|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. |
Headline News |
Tue, 26 Sep 2023
Is Innoviva Inc (INVA) a Leader in the Healthcare Sector? - InvestorsObserver
Sat, 23 Sep 2023
Reduction in Stake by Pacer Advisors Inc. Highlights Changing ... - Best Stocks
Sat, 23 Sep 2023
State Board of Administration of Florida Retirement System Sells ... - MarketBeat
Fri, 22 Sep 2023
Biotech Stocks Take Centerstage as Markets Turn Red (COEP,AMLX, BMRN, EXEL, HALO, INVA, MDXG, INCY, JAZZ, - Benzinga
Fri, 22 Sep 2023
Pacer Advisors Inc. Has $11.96 Million Holdings in Innoviva, Inc ... - MarketBeat
Tue, 19 Sep 2023
Innoviva to Participate in the Cantor Global Healthcare Conference - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
65 (M) |
| Shares Float |
53 (M) |
|
% Held by Insiders
|
1.3 (%) |
|
% Held by Institutions
|
110.3 (%) |
|
Shares Short
|
8,720 (K) |
|
Shares Short P.Month
|
8,390 (K) |
Stock Financials |
|
EPS
|
2.7 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.51 |
|
Profit Margin (%)
|
80.3 |
|
Operating Margin (%)
|
42.7 |
|
Return on Assets (ttm)
|
6.8 |
|
Return on Equity (ttm)
|
35.1 |
|
Qtrly Rev. Growth
|
-25.3 |
|
Gross Profit (p.s.)
|
4.24 |
|
Sales Per Share
|
4.46 |
|
EBITDA (p.s.)
|
2.12 |
|
Qtrly Earnings Growth
|
45 |
|
Operating Cash Flow
|
88 (M) |
|
Levered Free Cash Flow
|
80 (M) |
Stock Valuations |
|
PE Ratio
|
4.87 |
|
PEG Ratio
|
0.6 |
|
Price to Book value
|
1.54 |
|
Price to Sales
|
2.95 |
|
Price to Cash Flow
|
9.69 |
Stock Dividends |
|
Dividend
|
0.25 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1.8% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
